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Pierre De´voluy, 06000 Nice, FranceAbstract—Traumatic brain injury (TBI) is a frequent and clin-
ically highly heterogeneous neurological disorder with large
socioeconomic consequences. NeuroAid (MLC601 and
MLC901), a Traditional Medicine used in China for patients
after stroke has been previously reported to induce neuro-
protection and neuroplasticity. This study was designed to
evaluate the neuroprotective and neuroregenerative eﬀects
of MLC901 in a rat model of TBI. TBI was induced by a mod-
erate lateral ﬂuid percussion applied to the right parietal cor-
tex. MLC901 was injected intraperitoneally at 2 h post-TBI,
and then administered in drinking water at a concentration
of 10 mg/ml until sacriﬁce of the animals. The cognitive
deﬁcits induced by TBI were followed by using the ‘‘what-
where-when’’ task, which allows the measurement of
episodic-like memory. MLC901 treatment decreased brain
lesions induced by TBI. It prevented the serum increase of
S-100 beta (S100B) and neuron-speciﬁc enolase (NSE),
which may be markers to predict the neurologic outcome
in human patients with TBI. MLC901 reduced the infarct
volume when injected up to 2 h post-TBI, prevented edema
formation and assisted its resolution, probably via the regu-
lation of aquaporin 4. These positive MLC901 eﬀects were
associated with an upregulation of vascular endothelial
growth factor (VEGF) as well as an increase of endogenous
hippocampal neurogenesis and gliogenesis around the
lesion. Furthermore, MLC901 reduced cognitive deﬁcits
induced by TBI. Rats subjected to TBI displayed a suppres-
sion of temporal order memory, which was restored by
MLC901. This work provides evidence that MLC901 has
neuroprotective and neurorestorative actions, which lead
to an improvement in the recovery of cognitive functionshttp://dx.doi.org/10.1016/j.neuroscience.2014.06.047
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INTRODUCTION
Traumatic brain injury (TBI) is the leading cause of
mortality in the active/working population and a major
cause of disability in people under the age of 35 in
Europe and in the USA. With its socioeconomic
consequences and its high frequency in young adults,
TBI remains a major health problem worldwide and is
considered as a real challenge to public health (Bruns
and Hauser, 2003; Maas et al., 2008). Despite recent
advances in intensive care, the long-term disabilities sec-
ondary to brain injury, are still dramatic. 60% of patients
still display important after-eﬀects, particularly in cognitive
tasks (Ruttan et al., 2008). The complex physiopathology
of brain injury after trauma can explain the diﬃculty to
improve prognosis. TBI causes structural damage and
functional deﬁcits that are due to both primary and sec-
ondary injury mechanisms. Following the initial mechani-
cal insult leading to mechanical disruption of brain
tissue, secondary pathways are activated over minutes
to months after injury (Andriessen et al., 2010).
Despite a number of neuroprotective therapeutic
trials, no broadly applicable, safe and eﬃcacious
treatment for TBI has yet been identiﬁed (Xiong et al.,
2009). NeuroAid (MLC601/MLC901), a Traditional Chi-
nese Medicine (TCM) could represent a new approach
as therapeutic strategy against TBI. There are clinical
assays, including large-scale clinical trials on the use of
this treatment for stroke patients. Several molecular and
cellular demonstrations that this combination (mostly herb
extracts) targets important pathways of neuroprotection
and neurorepair have also been reported (Heurteaux
et al., 2013). Limited clinical studies on non-acute stroke
patients showed MLC601 improved recovery in terms of
functional outcome and neurological disability with a
good safety proﬁle (Gan et al., 2008; Siow, 2008; Bittner
et al., 2009; Chen et al., 2009; Kong et al., 2009; Young
et al., 2010; Bavarsad Shahripour et al., 2011;
Harandi et al., 2011; Navarro et al., 2013; Siddiquions.org/licenses/by-nc-nd/3.0/).
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CHInese Medicine NeuroAid Eﬃcacy on Stroke recovery)
study, which represents the ﬁrst large clinical trial of high
scale (more than 1000 patients) on a TCM in Neurology
(Venketasubramanian et al., 2009; Chen et al., 2013a),
MLC601 did not clearly demonstrate improvement of the
primary outcome but a reduction of early recurrent vascu-
lar events and vascular deaths in post-stroke patients has
been reported (Chen et al., 2013b). In addition, a recent
analysis on more than 500 patients within the CHIMES
cohort with more prognostic factors for poorer outcome
indicates a positive eﬀect of MLC601 (Navarro et al.,
2014). Interestingly, an Australian New Zealand clinical
trial including 140 patients with mild or moderate
traumatic brain injury and treated with NeuroAid supple-
mentation has been registered in 2013, proving the
interest of neurologists for this new potential strategy
against TBI (https://www.anzctr.org.au/Trial/Registration/
TrialReview.aspx?id=364449).
Consistent with observations of MLC601 eﬃciency in
humans, pharmacological data obtained in rodents have
established that MLC601 and MLC901 prevent death of
threatened neuronal tissues, decrease cognitive deﬁcits
and improve functional outcome by restoring neuronal
circuits in models of focal and global ischemia
(Heurteaux et al., 2010; Quintard et al., 2011). The eﬃ-
cacy of MLC601/MLC901 has also been demonstrated
in vitro in a model of excitotoxicity (Heurteaux et al.,
2010) and in a model of oxygen glucose deprivation
(OGD), which mimics ischemic conditions (Moha Ou
Maati et al., 2012). These interesting results led us to
evaluate the therapeutic eﬀectiveness of MLC901 in lat-
eral ﬂuid percussion (LFP)-induced TBI in rats. The pres-
ent work describes the protective/restorative eﬀects of
MLC901 against brain damage induced by TBI.EXPERIMENTAL PROCEDURES
Animals and ethical approval
All experiments were performed on male Sprague–
Dawley rats (300 g) from Janvier Laboratories (Saint-
Quentin Fallavier, France) and used according to
policies on the care and use of laboratory animals of
European Communities Council Directive (2010/63/
EU). The French ministry of higher education and
scientiﬁc research approved the experiments (protocol
number 00735-02). All eﬀorts were made to minimize
animal suﬀering and reduce the number of animals
used.LFP-induced brain injury
TBI of moderate severity was induced by LFP (Thompson
et al., 2005). In brief, rats were anesthetized by inhalation
of 2% isoﬂurane. Core temperature was monitored with a
rectal probe and body temperature was maintained at
37 C with a heating blanket during surgery. Animals were
placed in a Kopf stereotaxic frame. The scalp was incised
on the midline, and a 3-mm craniotomy was made lateral
to the right temporoparietal cortex (coordinates: 3.0 mm
anterior posterior and +3.5 mm mediolateral to bregma)with a dental drill, taking care to leave the dura mater
intact. A female Luer-Lok ﬁtting was placed over the dura
mater, ﬁxed securely into the craniotomy site with dental
cement, and then used to attach the rat to the FP injury
device. Lateral FP brain injury was induced using a device
consisting of a Plexiglas, cylindrical, saline-ﬁlled reservoir
bound at one end by a Plexiglas plunger mounted on O-
rings. The opposite end of the cylinder was capped with
a male Luer stub, which was connected to the rat via
the female Luer-Lok ﬁtting. A pendulum was allowed to
drop, striking the plunger and producing a calibrated out-
ﬂow pressure pulse of 2.2 atmospheres and of 20 ms in
duration via the rapid injection of saline into the closed
cranial cavity. The applied cortical pressure was mea-
sured extracranially by a pressure transducer connected
to an oscilloscope. Immediately after ﬂuid percussion,
the scalp was sutured under anesthesia, and the rats
returned to their home cage under temperature and
light-controlled conditions. Negative controls were sham-
operated rats. Each animal underwent the same surgery
except for percussion.Experimental design
Following TBI rats were randomly divided into three
groups: (i) sham-operated rats, (ii) vehicle-treated rats,
(iii) MLC901-treated rats. A supplementary sham-
operated group treated with MLC901 was used in the
behavioral experiments. MLC901 (Moleac, Singapore)
combines nine herbal components with the following
composition per capsule (Heurteaux et al., 2010): 0.57 g
Radix astragali, 0.114 g Radix salvia miltiorrhizae,
0.114 g Radix paeoniae rubra, 0.114 g Rhizoma
chuanxiong, 0.114 g Radix angelicae sinensis, 0.114 g
Carthamus tinctorius, 0.114 g Prunus persica, 0.114 g
Radix polygalae, 0.114 g Rhizoma acori tatarinowii.
MLC901 was diluted in saline (as vehicle) at the concen-
tration of 75 mg/ml (stock solution) and incubated under
agitation for 1 h at 37 C. The solution was then ﬁltered
with a 0.22-lm ﬁlter. For the time window of protection,
rats were intraperitoneally injected with a single dose of
MLC901 at a concentration of 0.075 mg/ml (in a bolus of
500 ll) 1, 2 or 3 h after TBI followed by an oral administra-
tion in drinking water (10 mg/ml) until the sacriﬁce of ani-
mals. The dose of MLC901 used was selected based on
our previous studies, where the injection of 0.075 mg/ml
of MLC901 in a bolus of 500 ll induced the best protec-
tion against global ischemia (Heurteaux et al., 2010;
Quintard et al., 2011). Once the time window of protection
was determined (from 1 to 2 h post-TBI, see Fig. 2D),
MLC901 was injected within this time window of
protection in all the following experiments. Following our
previous data on cerebral ischemia (Quintard et al.,
2011) and in relation to its previously observed potential
regenerative properties (Heurteaux et al., 2010;
Quintard et al., 2011), MLC901 was then given in drinking
water (10 mg/ml) until the sacriﬁce of rats at 7, 21 days or
10 weeks post-TBI. The ﬂowchart illustrating the experi-
mental design is given in Fig. 1. The researchers, who
carried out the TBI surgery and the measures of brain
injury were blinded in regard to the treatment code.
Fig. 1. Flowchart illustrating the diﬀerent in vivo paradigms. In A and B, rats were subjected to lateral ﬂuid percussion (TBI). (A) – MLC901 was
administered by intraperitoneal injection (0.075 mg/ml) at 1, 2 or 3 h post-TBI for the determination of the time window of protection. For the other
experiments, MLC 901 was injected at 1 or 2 h post-TBI and then administered during 7 days in the drinking water (10 mg/ml). In red and blue is
indicated the technical approach used with the corresponding MLC901 treatment (arrow in red or blue) and in green the type of experiment. (B) –
MLC901 (0.075 mg/ml) was injected at 2 h post-TBI and then administered in the drinking water (10 mg/ml) during 7 or 21 days for the determination
of neurogenesis and during 10 weeks for the retrograde neuronal ﬂuorogold (FG) tracing. In blue is indicated the technical approach used with the
corresponding MLC901 treatment (arrow blue) and in green the type of experiment. For the neurogenesis study, rats received the day of TBI 4 BrdU
intraperitoneal injections (75 mg/kg) at 2-h intervals. For the retrograde neuronal FG study, rats were once injected with BRDU (75 mg/kg) at 2, 3
and 4 days post-TBI and received a 2% FG injection 8 weeks after TBI.
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zolium chloride (TTC), acid fuchsin and Fluoro-Jade
B stainings
The visualization of the lesion extent was ﬁrstly obtained
from TTC staining as previously described (Heurteaux
et al., 2006). The density of injured neurons, i.e. the num-
ber of injured cells per mm2 of injured tissue was quanti-
ﬁed. A mean value for each brain area was obtained
from 10 measurements/section on two sections per slide
and 10 slides per rat, for the six animals in each experi-
mental group. Neuronal density values are expressed as
mean ± S.D. Fluoro-Jade B staining, which labels degen-
erative neurons was performed according to the protocol
described by Schmued et al. (1997).
Lesion volume analysis on Cresyl Violet stained
sections
Every 10th coronal brain section (20 lm) throughout the
brain was stained with Cresyl Violet. Photomicrographs
were captured using an Olympus microscope and lesionarea was determined by using the Olympus Image
software. The Cavalieri formula was used to calculate
total lesion volume [Volume = RS  t  ISF] where
S= sum of the corrected lesion area surfaces (mm2),
t= section thickness (20 lm) and ISF = inverse of the
sampling fraction (1 in 10 sections was counted, i.e.
sampling fraction 1/10) (n= 6 for each experimental
group).
Brain edema
Cerebral edema was determined at 24 h post-TBI by
measuring brain water content (BWC) using the wet
weight–dry technique (Chen et al., 2008).
Serum quantitation of biochemical markers of
traumatic brain injury in the blood: S-100 beta
(S100B) and neuron-speciﬁc enolase (NSE)
measurements
Serum samples were collected on ‘‘Vacuette’’ Z
serum Sep clot activator at 10 min, 2, 6 and 24 h after
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using the Diasorin Liaison XL chemiluminescence
immunoassay (Bloomﬁeld et al., 2007).Immunohistochemistry and Western blotting
Coronal brain sections (40-lm thick) were cut on a
vibratome (Leica) and conserved at 20 C in
‘‘antifreeze’’ medium as previously described (Heurteaux
et al., 2010). The antibodies used were the rabbit poly-
clonal Aquaporin 4 (AQP4) (Antibodies Online, Atlanta,
USA, ABIN4984643, diluted 1/300), microtubule-associ-
ated protein 2 (MAP2) (1:200, Chemicon International,
Merck-Millipore, Saint-Quentin, France) or glial ﬁbrillary
acidic protein (GFAP) (1:300, SC6170, Santa Cruz,
CliniSciences, Nanterre, France) antibodies. For quantiﬁ-
cation of protein abundance in the brain tissue, Western
blot analysis was performed as previously described
(Heurteaux et al., 2010). The blotted membrane was incu-
bated with the following rabbit or goat polyclonal primary
antibodies: AQP4 (Antibodies Online, Atlanta, USA,
ABIN4984643, diluted 1/300) or vascular endothelial
growth factor (VEGF) (1/500, Santa Cruz, CliniSciences,
Nanterre, France, SC-1836). Analysis of the ﬂuorescence
intensity was performed by using the NIH Image J soft-
ware (http://rsbwebnih.gov/ij), which allowed to extract
the ﬂuorescent intensity levels of cells of each ﬂuorescent
image saved as a 16-bit TIFF ﬁle (n= 3 cultures, 12 wells
per experimental group, total 15 ﬁelds per condition).
Results are given as ratio of mean ﬂuorescence intensity
in AU (arbitrary unit)/number of labeled cells ± SEM of
three experiments.Analysis of in vivo neurogenesis on brain sections
5-bromo-20-deoxyuridine (BrdU) treatment consisted of 4
injections (75 mg/kg, i.p. each, 2 h interval) the day of
the injury. Brains were removed at 24 h after the last
BrdU injection. Every sixth section (40 lm) cut
throughout the hippocampus was processed for
immunohistochemistry using a monoclonal mouse anti-
BrdU (1/200; BD Biosciences, Le Pont de Claix, France)
(Heurteaux et al., 2010). The phenotype of BrdU-positive
cells was determined using ﬂuorescent double-labeling
with the following antibodies and dilutions: sheep
anti-BrdU (1:200, Interchim, Montluc¸on, France), goat
anti-DCX (doublecortin, 1/200, Santa Cruz Laboratories,
CliniSciences, Nanterre, France), mouse anti-NeuN (neu-
ron-speciﬁc nuclear protein, 1/250, Millipore, Molsheim,
France), rabbit anti-GFAP (glial ﬁbrillary acidic protein,
1/250, Dako, Les Ulis, France) and secondary antibodies
conjugated with Alexa Fluor 488 or 594 (1/1000; Molecu-
lar Probes, Life Technologies SAS, Saint-Aubin, France).Neuronal tracer injection
At day 2, 3 and 4 post-TBI, rats were injected with BrdU.
Eight weeks after TBI, rats received a bilateral stereotaxic
injection of FluoroGold (Fluorochrome INC., Denver,
USA), a retrograde neuronal tracer (Sun et al., 2007).
The coordinates for the CA3 injection were from bregma:
anterior–posterior, 3.3 mm; medial–lateral, 3.2 mm, andthe depth from the pial surface, 3.4 mm. Two weeks
after FG injection, rats were transcardially perfused with
4% paraformaldehyde and processed for immunohisto-
chemistry as described above.
Behavior: the ‘‘what-where-when’’ task
Seven days (D + 7) after TBI, rats were tested for
cognitive deﬁcits using a modiﬁed version of object
recognition task called the ‘‘what-where-when’’ test. The
animals were still being treated with MLC901 during the
period of behavioral testing. This test allows to
investigate all the aspects of episodic-like memory in
rodents (Dere et al., 2005; Barbosa et al., 2010). The test
comprises three object exploration trials, designed to
simultaneously subsume (i) the memory for location in
which objects were explored (‘‘what-where’’), and (ii) the
temporal order memory for objects presented at distinct
time points (‘‘what-when’’). The device was an open ﬁeld
made of painted wood, 75 cm square by height 30 cm,
and indirectly lit by two halogen lamps (50 lx illumination).
Geometric cues were arranged in a spatial frame around
the apparatus. Two sets of 4 objects diﬀering in terms of
height, color and shape were used. At D + 7 after TBI
each rat received two sample trials and a test trial
(7 min). In the ﬁrst Sample trial (Sample 1), rats were
placed in the open-ﬁeld to explore freely the four copies
of a same object (Fig. 6A). After a delay of 90 min, rats
received a second Sample trial (Sample 2) by replacing
the 4 objects by 4 novel objects, arranged in a diﬀerent
spatial conﬁguration. After a delay of 180 min, rats
received a test trial identical to the second sample trial,
except that 2 objects from Sample 1 trial (‘‘old’’ objects)
and 2 objects known from Sample 2 trial (‘‘recent’’
objects) were present. Furthermore, one of the two
‘‘old’’ objects was shifted to a novel location, whereas
both the ‘‘recent’’ objects were presented at identical
locations (Fig. 6A).
The behavior of rats was analyzed by ANY-maze
tracking software (Anymaze, Stoelting, Wood Dale,
USA). The time spent exploring each object was scored
and the total exploratory activity was then calculated
(sum of the exploration time for each object). We
expressed the spatial memory index (‘‘what-where’’
memory) as the preference for the ‘‘displaced’’ old
object compared to the ‘‘stationary’’ old object calculated
with the following formula:(time spent exploring the
‘‘displaced’’ old object – time spent exploring the
‘‘stationary’’ old object)/time spent exploring both ‘‘old’’
objects’’. The old objects preference index reﬂecting the
temporal order memory (‘‘what-when’’ memory) was
calculated as follows:(time spent exploring both old
objects – time spent exploring both recent objects)/total
exploration time. Results analysis was restricted to the
ﬁrst 6.5 min of the trials in order to minimize the impact
of the object preference erosion naturally occurring with
time. The time spent by the rats in the central area of
the apparatus (45 cm square) was measured to serve
as index of anxiety.
For statistical analysis, the data distribution normality
and homoscedasticity were checked using Shapiro–Wilk
test for normality and Levene’s test for equality of error
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(surgery  treatment) analysis of variance (ANOVA)
were never fulﬁlled. As a consequence, paired and
unpaired comparisons were achieved by performing
Wilcoxon and Mann–Whitney tests, respectively. In
order to verify rats discriminated the stationary ‘‘old’’
object (when compared to the displaced ‘‘old’’ one) and
both ‘‘old’’ objects (when compared to ‘‘recent’’ ones)
above chance level, we used a Mann–Whitney test (with
theoretical mean mu = 0). In all cases, statistical
signiﬁcance was accepted as P< 0.05.RESULTS
Neuroprotective eﬀect of MLC901 on the brain
damage induced by TBI
As compared to sham-operated uninjured rats, animals
subjected to TBI presented neuronal lesions, which
were most severe in brain regions surrounding the
impact site. Representative photographs of brain slices
stained with TTC at the level of the cerebral cortex are
shown at 24 h following TBI in Fig. 2A. As indicated by
the reduction of the white area on TTC-stained brain
slices, cortical infarcts in rats treated with MCL901,
administered 2 h after TBI, were strongly reduced. The
beneﬁcial eﬀect of MLC901 was conﬁrmed by the
quantitative assessment of total lesion volume on Cresyl
Violet-stained brain sections at diﬀerent times following
TBI. At 6 h post-TBI, the brain lesion reached a volume
of 92.5 ± 10.3 mm3 that was signiﬁcantly reduced to
64.5 ± 7 mm3 by the MLC901-treatment (P< 0.05
versus vehicle group) (Fig. 2B). This treatment provided
a long-lasting protective eﬀect since the decrease of the
lesion volume by MLC901 was sustained at 7 days post-
TBI (43% reduction). The acid fuchsin staining allows
to identify injured neurons and follows the speciﬁc
temporal and regional neuronal injury associated to TBI.
At 6 h following TBI the progressive increase in the
number of injured neurons in the ipsilateral hippocampal
CA3 substructure, dentate gyrus and thalamus of
vehicle-treated rats was signiﬁcantly reduced by
MLC901 (Fig 2C, upper panel). Representative
photomicrographs of the hippocampal CA3 region on
acid fuchsin or Fluoro-Jade B-stained brain sections
highlighted the neuronal degeneration induced by TBI
and the potent protective eﬀect of MLC901 treatment
6 h after TBI (Fig. 2C, upper panel). Injured neurons
stained by acid fuchsin appeared small and round and
were surrounded by vacuoles. As compared to vehicle-
treated rats, the number of acid fuchsin-positive neurons
was strongly decreased in the CA3 area of MLC901-
treated rats. (Fig. 2C, bottom panel). Fluoro-Jade B
staining, in which degenerative neurons appeared in
green, demonstrated a strong neuronal degeneration in
vehicle-treated rats (Fig. 2C, upper panel, right side).
TBI-induced necrotic and apoptotic neuronal death was
signiﬁcantly reduced after a MLC901-treatment
(Fig. 2C). The MLC901 time window of protection was
determined by i.p. injection of 0.075 mg/ml (in a bolus of
500 ll) 1, 2 or 3 h post-TBI followed by an oral
administration of MLC901 in drinking water at theconcentration of 10 mg/ml until sacriﬁce at 7 days
(Fig. 2D). The MLC901 treatment provided a signiﬁcant
protection when the ﬁrst injection was within 2 h
following TBI. When treatment was delayed to 3 h after
TBI, the number of surviving cortical neurons was
comparable to that observed in vehicle-treated rats
(P> 0.05), suggesting that the capacity to protect was
lost after 3 h following TBI.Eﬀect of MLC901 on reactive astrocytes and dendritic
damage
GFAP is the cell-speciﬁc intermediate ﬁlament in
astrocytes and the upregulation of its synthesis is
considered a deﬁnite feature of activated astrocytes
(Kernie et al., 2001). Clearly, a positive GFAP staining
was observed both in the injured cortex and dentate gyrus
of vehicle-treated rats but not of the sham-operated ani-
mals at 24 h following TBI. MLC901 strongly decreased
GFAP expression in both injured structures (Fig. 3A, B).
A quantitative analysis (Fig. 3C, D) showed that GFAP
expression was respectively increased 1.80 and 3.0-fold
in the cortex and the dentate gyrus of vehicle-treated rats
as compared to the sham group (⁄⁄P< 0.01). A MLC901
treatment allowed to return to sham levels of GFAP
expression in both cerebral structures.
The MAP2 is abundantly expressed in the soma and
dendrites of neuronal cells. MAP2 is important for
microtubule stability and neural plasticity. Alterations in
MAP2 expression are of key importance in neuronal
degeneration following brain injury (Johnson and Jope,
1992). At 4 h following TBI, we observed a strong
decrease of MAP2 expression in the CA3 region as well
as in the dentate gyrus of injured vehicle-treated rats.
This MAP2 alteration was prevented in MLC901-treated
rats (Fig. 3B–E). The quantitative analysis of MAP2
expression in the dentate gyrus and the hippocampal
CA3 substructure conﬁrmed the result (Fig. 3D–F). In
the CA3 of vehicle-treated rats, the levels of MAP2
expression were signiﬁcantly 1.48-fold decreased as
compared to sham rats, whereas in the MLC901-treted
animals they were comparable to those observed in the
sham group (⁄⁄P< 0.01). This result suggests that
MLC901 reduces dendritic damage in the spared neurons
after TBI.Eﬀect of MLC901 on serum protein biomarkers,
S100B and NSE
Then, we analyzed the concentration of two predictive
serum markers, S100B and NSE, used for trying to
predict the neurologic outcome in human patients with
TBI (Kovesdi et al., 2010; Giacoppo et al., 2012). Signiﬁ-
cant increases in serum S100B and NSE levels were
detected up to 6 h post-TBI in vehicle-treated rats as com-
pared to sham-operated animals (⁄P< 0.05 versus sham
group; Fig. 4). A peak was observed for both proteins at
2 h following TBI. Very interestingly, MLC901, which
was injected 1 h post-TBI strongly prevented this serum
increase of both S100B and NSE (#P< 0.05 versus vehi-
cle-treated TBI group; Fig. 4).
Fig. 2. Neuroprotective eﬀects of MLC901 in rats subjected to TBI, highlighting by TTC, Acid Fuchsin, Fluoro-Jade and Cresyl Violet stainings. (A) –
Representative photographs of coronal TTC-stained brain sections 24 h after TBI. MLC901 was i.p. injected 2 h after TBI at a concentration of
0.075 mg/ml (500 ll/rat). (B) – Volume of cortical damage (mm3) at diﬀerent times after TBI assessed by Cresyl Violet staining. Animals received an
i.p.MLC901 injection (0.075 mg/ml in a bolus of 500 ll) 2 h post-TBI followed by an oral administration in drinking water (10 mg/ml) for 7 days. Rats
were sacriﬁced at 6, 24 h or 7 days post-TBI. (C) Upper panel – Representative photographs of Acid Fuchsin- (left side) or Fluoro-Jade (right side)-
stained hippocampal brain sections 6 h after TBI. Scale bars = 25 and 10 lm, respectively. (C) Bottom panel – Number of acid fuchsin-positive
cells per mm2 in CA3, dentate gyrus and thalamus at 6 h after TBI (n= 6 rats per experimental group). (D) – Time window of protection of a MLC
treatment (0.075 mg/ml) on the neuronal density per mm2 7 days after TBI. (n= 6 per experimental group, ⁄P< 0.05 versus vehicle TBI group,
#P< 0.05 versus sham group). Data are mean ± SEM assessed by ANOVA and post hoc Tukey’s w test. (n= 6 per experimental group). Values
in columns represent the percentage of reduction in lesion volume.
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aquaporin expression
Cerebral edema was determined by measuring BWC in
cortical segments. Edema formation was evaluated at
24 h post-injury. As previously observed (Shenaq et al.,
2012; Khaksari et al., 2013; Du et al., 2013), BWC in
sham-operated rats was around 71%. TBI led to an
increase of the BWC, demonstrating a brain edema within
the ipsilateral injured hemisphere (77.3 ± 0.5%)
(Fig. 5A). BWC was signiﬁcantly reduced by the
MLC901-treatment administered 2 h after TBI
(71.9 ± 0.5%, ⁄P< 0.05).
Aquaporins (AQPs), and in particular AQP4, the most
abundant AQP in the brain, have dual roles in the
formation and then the resolution of edema after brain
injury (Badaut et al., 2011). Early inhibition of the water
channels has positive eﬀects in the prevention of edema
formation. However, at a later time point, during thecourse of brain injury (few days), AQP4 is important for
the clearance of water from the brain to the blood vessels
(Fukuda and Badaut, 2012). Using Western blotting
assay, AQP4 protein expression was found to be signiﬁ-
cantly reduced (20%) in the ipsilateral cortex of vehi-
cle-treated group as compared to sham-operated
animals 2 h following TBI (P< 0.05) (Fig. 5B). This
decrease of AQP4 expression was more pronounced in
rats treated with MLC901 1 h post-TBI (40%). In con-
trast, 7 days following TBI, we observed a strong increase
of AQP4 expression in MLC901-treated group as com-
pared to vehicle-treated rats (Fig. 5B). Two hours follow-
ing TBI, the high AQP4 immunolabeling was diﬀusely
distributed within the contusional cortex of vehicle-treated
rats, and was strongly decreased in the MLC901-treated
animals (Fig. 5C, upper panel). In contrast, at 7 days
post-TBI, MLC901 induced an increase in AQP4 expres-
sion, which was mainly located at the periphery of blood
vessels (Fig. 5C, bottom panel).
Fig. 3. MLC901 prevents the upregulation of GFAP and the alteration of MAP2 expression induced by TBI. (A) – GFAP immunolabeling (green) in a
portion of the ipsilateral cortex adjacent to the lesion observed in sham-operated, TBI-vehicle- or MLC901-treated rats at 24 days following TBI
(Scale bar = 15 lm). (B) – Double-labeling of GFAP (red) and MAP2 (green) in dentate gyrus from 3 experimental groups (Scale bar = 20 lm). (C
and D) – Quantiﬁcation of GFAP and MAP2 signal intensity in immunostained neurons of the cortex and dentate gyrus. Data are expressed as ratio
of mean ﬂuorescence intensity in AU (arbitrary unit  1000) to number of labeled cells ± SEM. Average ﬂuorescence intensity was expressed from
two independent experiments (n= 8 sections per experimental group, 15 ﬁelds per section and analyzed in triplicate) (⁄⁄P< 0.01, ⁄P< 0.05
versus sham and MLC901 groups). (E) – MAP2 peroxidase-immunostaining in hippocampal CA3 region from 3 experimental groups 4 h post-TBI.
Scale Bar = 50 lm. Bottom panels – High-magniﬁcation photomicrographs of the boxed area in upper panels showing in more detail the pattern of
MAP2 immunolabeling. Scale Bar = 10 lm. Animals received an i.p. MLC901 injection (0.075 mg/ml in a bolus of 500 ll) 2 h post-TBI. (F) –
Quantiﬁcation of MAP2 signal intensity in immunostained neurons of CA3 substructure. Data are expressed as ratio of mean signal intensity in AU
(arbitrary unit x1000) to number of labeled cells ± SEM as described above. (⁄⁄P< 0.01 versus sham and MLC901 groups).
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VEGF by MLC901 after TBI
The release and up-regulation of endogenous
neurotrophic factors such as BDNF (brain-derived
neurotrophic factor) and VEGF is an important
mechanism in neuronal repair after brain damage
(Ferrara, 2004). MLC901 is known to stimulate BDNF
expression in brain tissue after focal and global ischemia
(Heurteaux et al., 2010; Quintard et al., 2011). In this work,
we evaluated 7 days after TBI changes in VEGF expres-
sion in the ipsilateral cortex and hippocampus of vehicle-
and MLC901-treated rats by using Western blot assays.
VEGF levels signiﬁcantly increased in hippocampus and
not in the cortex of vehicle-treated rats at 7 days post-
TBI (Fig. 5D, ⁄P< 0.05). MLC901 signiﬁcantly stimulated
VEGF expression both in hippocampus and cortex of ani-
mals as compared to the vehicle-treated group
(#P< 0.05).Post-TBI stimulation of hippocampal neurogenesis
and gliogenesis around the lesion by MLC901
Traumatic injury stimulates neurogenesis in the dentate
subgranular cell layer (SGZ) (Nakatomi et al., 2002).
However brain self-repair by spontaneous neurogenesis
is not suﬃcient to induce an extensive recovery. To test
the MLC901 potential in enhancing hippocampal neuro-
genesis, the incorporation of BrdU (5-bromo-20-deoxyuri-
dine, a DNA synthesis marker) in dividing progenitor
cells, corresponding to the production of newborn neu-
rons was analyzed 7 and 21 days after TBI. One week
after TBI, the number of BrdU-positive cells increased
three-fold in the ipsilateral hippocampus of the TBI vehi-
cle-group, compared to that observed in the sham-oper-
ated group (Fig. 6A, ⁄P< 0.05). MLC901 increased 2.6-
fold the number of BrdU-positive cells in the DG as com-
pared to the vehicle-treated group 7 days after TBI
(#P< 0.05) (Fig. 6A). The phenotype of BrdU-positive
Fig. 4. Eﬀect of MLC901 on the serum concentrations of S100B and
NSE (ng/ml), used as biomarkers at diﬀerent times after TBI. Rats
received an i.p. MLC901 injection 1 h following TBI. Data are
mean ± SEM (n= 6 per experimental group, ⁄P< 0.05 versus
sham operated group, #P< 0.05 versus vehicle TBI group).
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DCX, a microtubule-associated protein that is speciﬁcally
expressed in migrating neuronal precursors and in areas
of continuous neurogenesis in the adult brain for neurons.
Many of the DCX-labeled cells were closely associated
with BrdU in DG (Fig. 6B). BrdU+ cells did not co-localize
with GFAP. Twenty-one days after TBI, the number of
BrdU-positive cells in MLC901-treated injured group was
still signiﬁcantly increased as compared to that observed
in the vehicle-treated injured group (#P< 0.05, Fig. 6A–
C). At day 21 post-TBI, ﬂuorescent double labeling for
BrdU and NeuN (a mature neuron marker) was performed
to follow the diﬀerentiation of the new proliferating cells.
MLC901 signiﬁcantly increased the percentage of BrdU/
NeuN co-labeled cells in the DG (59.8% in MLC901 group
versus 18.4% in the vehicle group). At 21 days following
TBI, we also observed an increase in the number of
BrdU-positive cells in the area surrounding the injured
cortex of vehicle-treated rats as compared to the sham-
operated group. Interestingly, MLC901 strongly increased
the BrdU labeling in the same injured area (Fig. 6D).
BrdU-positive cells co-localized with GFAP suggesting
that these newly generated cells within the entire region
around the injured site had matured to fully diﬀerentiated
astrocytes. These results are in favor of a regenerative
potential of MLC901 to replenish the population of
damaged and/or destroyed cells.To analyze whether new mature granule neurons
generated following TBI can establish the correct
anatomical connection to the existing hippocampal
circuitry, rats were intraperitoneally injected with BrdU at
Day 2, 3 and 4 post-TBI, followed 8 weeks later by the
injection of the retrograde neuronal tracer FG into the
granule cell target structure, CA3 (Sun et al., 2007). Ani-
mals were allowed to survive 2 additional weeks to pro-
vide suﬃcient time for retrograde transportation of FG
from the CA3 to the DG granular layer. Using a confocal
microscope, we observed that the hippocampal FG injec-
tion induced an intense labeling of the neuronal cell
bodies in the granule cell layer, which retrogradely incor-
porated the ﬂuorescent dye (Fig. 6F) in all experimental
groups. Then, to determine whether the newly generated
cells retrogradely labeled with FG, we observed BrdU+
cells which were colocalized with FG in the dentate gyrus
of both injured vehicle- and MLC901-treated rats
(Fig. 6G). It then appeared that MLC901 increased the
number of BrdU/FG double-labeled cells, indicating that
MLC901, which stimulates hippocampal neurogenesis
also increases the number of axons of newly generated
cells to the CA3 region (Fig. 6G).
Improvement in cognitive function recovery by
MLC901
TBI induces reproducible cognitive deﬁcits which can be
measured by using the ‘‘what, where, when’’ task
(Fig. 7A). To ensure that anxiety is not involved in the
behavior of rats in this task, we measured the time
spent in the center of the open ﬁeld (a classical index of
anxiety). The results showed that this time duration was
dependent neither on the treatment received (Vehicle vs
MLC901) nor on the fact that animals were exposed to
lateral percussion (Sham vs TBI) (Fig. 7B). Thus, the
anxiety level of animals in our conditions is unlikely to
account for the diﬀerences of object preference
observed between groups. In Fig. 7C, we observed that
both TBI groups, with or without MLC901 treatment,
signiﬁcantly displayed decreased exploratory activity
toward all objects (=total exploratory activity) when
compared to respective sham groups during samples
trials (Fig. 7C; U= 15, ⁄⁄P< 0.01 for Vehicle-TBI rats).
This drop of exploration capacity was also observed in
the test trial, but only signiﬁcant in the MLC901-TBI
group (Fig. 7C; ⁄P< 0.05). All rats spent less time
exploring the objects during the test trials than during
the sample trials, probably due to habituation to the
experimental environment. This diﬀerence was
signiﬁcant for the four groups (Fig. 7C; Vehicle-Sham:
T= 8; $P< 0.05/MLC901-Sham: T= 0; $$P< 0.01/
Vehicle-TBI: T= 2; $$P< 0.01/MLC901-TBI: T= 1;
$P< 0.05). In the analysis of temporal order memory,
the two sham groups (vehicle and MLC901) showed a
signiﬁcant preference for the ‘‘old’’ objects (Fig. 7D;
Vehicle-Sham: U= 55; ##P< 0.01/MLC901-Sham:
U= 65; ##P< 0.01). There was no signiﬁcant
diﬀerence (Fig. 7D; U= 35; P> 0.05), when we
compared the Vehicle-Sham rats to MLC901-Sham rats,
suggesting an absence of drug eﬀect on sham animals
in the temporal task. TBI totally abolished the
Fig. 5. Eﬀect of MLC901 on cerebral edema formation, AQP4 and VEGF expression in rats subjected to a lateral ﬂuid percussion-induced TBI. (A) –
Brain water content 24 h post-TBI. It was measured in ipsilateral contusional cortical segments and presented as percentage of water content. Data
are mean ± SEM (n= 6 per experimental group, ⁄P< 0.05 versus sham operated group and #P< 0.05 versus vehicle TBI group). Rats received
an i.p. MLC901 injection 2 h following TBI. (B) – AQP4 expression (30 kDa) in injured cortical tissue determined by Western blotting analysis at 2 h
and 7 days post-TBI. Tubulin was used as internal control for the loading of protein level. Left panel: Western blot, Right panel: Quantitation of AQP4
expression obtained in Western blots in the 3 experimental groups. Values are expressed as a percentage of control. Data are mean ± SEM
(⁄P< 0.05 versus sham operated group and #P< 0.05 versus vehicle TBI group). (C) – Representative photomicrographs of the MLC901-induced
decrease of AQP4 immunolabeling (in green) in the ipsilateral injured cortex at 24 h post-TBI (Left panel) and the MLC901-induced increase of
AQP4 immunolabeling at the periphery of blood vessels at 7 days post-TBI (Right panel). (D) Western blotting analysis of brain VEGF expression
(Upper panel) and its quantitation (Bottom panel) in the hippocampal and cortical samples from sham-operated, TBI vehicle- or MLC901-treated rats
at 7 days post-TBI. The band of VEGF was observed at 42 kDa in the whole-cell fraction from rat brains. Actin was used as internal control.
Histograms represent relative VEGF expression obtained in Western blotting in the 3 experimental groups. Values are expressed as a percentage of
control. Data are mean ± SEM assessed by ANOVA and post hoc Tukey’s w test, ⁄P< 0.05 versus sham-operated group, #P< 0.05 versus
vehicle TBI group. MLC901 was i.p injected 2 h after TBI followed by an oral administration in drinking water (10 mg/ml) during 7 days after traumatic
injury. Western blots data are representative of 3 separate experiments (n= 6 per group).
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failed to discriminate between the two ‘‘old’’ objects and
the two ‘‘recent’’ ones. They did not perform above
chance level (Fig. 7D; U= 42.5; P> 0.05). Very
interestingly, MLC901 completely reversed this severe
impairment and restored the performance of the
MLC901-treated TBI rats to that observed in sham rats
(Fig. 7D; U= 42; #P< 0.05). The MLC901-TBI rats
performances were above chance level and similar to
those of MLC901-Sham rats. In addition, the old objects
preference index was signiﬁcantly higher in the
MLC901-TBI rats than in the Vehicle-TBI rats
(§P< 0.05). These results showed that MLC901 allows
the recovery of the temporal order memory, which is
impaired after TBI. In term of object location (spatial)
memory (old ‘‘stationary’’ object versus old ‘‘displaced’’
object), vehicle-treated rats, with or without TBI, did notshow preference for any of the ‘‘old’’ objects. They did
not signiﬁcantly perform above chance level (Fig. 7D
Inset; Vehicle-Sham: U= 21; P> 0.05/Vehicle-TBI:
U= 45; P> 0.05). There was no signiﬁcant diﬀerence
between the Vehicle-Sham and Vehicle-TBI groups for
the spatial preference index (Fig. 7D Inset; U= 29;
P> 0.05). In contrast, both Sham-rats and TBI-animals
treated with MLC901 spatially discriminated between the
two ‘‘old’’ objects with a similar level of performance.
They performed above chance level in exploring the
‘‘displaced’’ and the ‘‘stationary’’ objects and showed a
preference for the ‘‘stationary’’ object (Fig. 7D Inset;
preference for the ‘‘stationary’’ object versus the
‘‘displaced’’ object: MLC901-Sham: U= 48; #P< 0.05/
MLC901-TBI: U= 42; #P< 0.05). These results show
that MLC901 itself has a positive eﬀect on object
location (spatial) memory, which is maintained in TBI-rats.
Fig. 6. Stimulating eﬀect of MLC901 on neurogenesis induced by TBI. (A) – Quantitation of BrdU-positive cells per hippocampus from sham-
operated, TBI-vehicle- or MLC901-treated rats at 7 and 21 days after TBI. Data are expressed as mean ± SEM (3 independent experiments from
n= 6 per group, 8 sections per group, 10 ﬁelds per section, chosen randomly; ⁄P< 0.05 versus sham-operated group, #P< 0.05 versus TBI
vehicle-treated rats). (B) – Upper Panel: Double-labeling of BrdU-labeled neurons (in green) with DCX neuronal precursor marker (in red) 24 h after
TBI. Scale Bar = 5 lm. Arrows indicate the BrdU/DCX co-localization. Bottom panel: Double-labeling of BrdU-labeled neurons (in green) with
GFAP, an astrocyte marker (in red) 24 h after TBI. (C) – Representative photomicrographs of BrdU peroxidase-staining (arrows) in hippocampal
dentate gyrus from the 3 experimental groups 21 days after TBI. Scale Bar = 20 lm. (D) – Intense MLC901-induced increase of BrdU labeling
(arrows) in the proximal cortical injury zone 21 days after TBI. Scale Bar = 30 lm. (E) – Double-labeling of BrdU-labeled neurons (in green) with
GFAP (in red) 21 days after TBI. Arrows indicate the BrdU/GFAP co-localization. (F) – Hippocampal coronal section of a MLC901-treated TBI rat
that had received a FluoroGold (FG) injection in the CA3 region at 8 weeks post-TBI. The neuronal cell bodies in the granule cell layer, which
retrogradely incorporated FG, are apparent in the boxed area. Scale Bar = 100 lm. (G) – Confocal micrograph in F showing co-localization
(arrows) of BrdU (green) Scale Bar = 5 lm. (red), highlighting the projection of axons of newly generated neurons to the hippocampal CA3 region.
Rats were i.p. injected with a single dose of MLC901 (0.075 mg/ml in a bolus of 500 ll) 2 h after TBI followed by an oral administration in drinking
water (10 mg/ml) until sacriﬁce.
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Due to the complexity of TBI, there is increasing evidence
that the search for a drug which speciﬁcally acts on a
single target is exceeded and that combination therapiescomprising more than one active ingredient can
represent a better strategy. Interestingly, combination
therapy has been advocated for centuries by
prescriptions of formulae in TCM to treat a wide variety
of ailments. TCM, which is based on clinical experience
Fig. 7. MLC901 reverses TBI-related impairments of the episodic memory in the ‘‘what, when, where’’ task. The experimental groups were as
follows: Vehicle-Sham, n= 10; MLC901-Sham, n= 11; Vehicle-TBI, n= 10; MLC901-TBI, n= 9. MLC901 (0.075 mg/ml, 500 ml/rat) was i.p
injected 2 h post-TBI followed by an oral administration in drinking water (10 mg/ml) during 7 days. All values are mean ± SEM. (A) – Schematic
drawing of the experimental design used. (B) – Anxiety level of animals. Neither the surgery nor MLC901 modiﬁed the anxiety-related behaviors of
mice as detected by the time spent in the central area of the open ﬁeld. All values are mean ± SEM. Sample 1 trial: Vehicle-Sham vs MLC901-
Sham: U= 52; P> 0.05/Vehicle-TBI vs MLC901-TBI: U= 25.5; P> 0.05/Vehicle-Sham vs Vehicle-TBI: U= 37.5; P> 0.05/MLC901-Sham vs
MLC901-TBI: U= 41; P> 0.05. (C) – Total exploratory activity. Only the ﬁrst 6.5 minutes of each trial were considered. The samples exploratory
time was obtained by averaging the sample 1 and sample 2 exploratory times. Comparison between Vehicle-Sham and Vehicle-TBI rats during the
Samples trials: U= 15; ⁄⁄P< 0.01. Comparison between Samples and Test exploratory times: Vehicle-Sham: T= 8; $P< 0.05/MLC901-Sham:
T= 0; $$P< 0.01/Vehicle-TBI: T= 2; $$P< 0.01/MLC901-TBI: T= 1; $P< 0.05. (D) – Temporal order memory as denoted by preference index
for the ‘‘old’’ objects during the ﬁrst 6.5-min trial test. Comparison to chance level: Vehicle-Sham: U= 55; ##P< 0.01/MLC901-Sham: U= 65;
##P< 0.01/Vehicle-TBI: U= 42.5; NSP> 0.05/MLC901-TBI: U= 42; #P< 0.05. Comparison between Vehicle-TBI and MLC901-TBI: U= 18;
§P< 0.05. Inset: Object location (spatial) memory as denoted by the preference index for the ‘‘stationary’’ versus the ‘‘displaced’’ old object during
the ﬁrst 6.5-min trial test. Comparison to chance level: Vehicle-Sham: U= 21; NSP> 0.05/Vehicle-TBI: U= 45; > 0.05/MLC901-Sham: U= 48;
#P< 0.05/MLC901-TBI: U= 42; #P< 0.05.
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types of medicinal herb extracts, has now attracted
increasing attention both from industry and academia.
As recently shown for promyelocytic leukemia, Chinese
herbal medicines can now represent a new promising
area in drug discovery (Wang et al., 2008). Among all her-
bal Chinese formulae proposed for cerebrovascular dis-
eases, NeuroAid has recently emerged as a promising
treatment against stroke. Several clinical trials and reports
have revealed a high level of safety (Gan et al., 2008;
Young et al., 2010; Harandi et al., 2011; Siddiqui et al.,
2013) as well as eﬃciency in improving cerebral blood ﬂow
velocity and stroke rehabilitation, even at a late stage
(Siow, 2008; Gan et al., 2008; Chen et al., 2009; Kong
et al., 2009; Venketasubramanian et al., 2009; Bavarsad
Shahripour et al., 2011; Navarro et al., 2013). The
CHIMES trial (Chen et al., 2013a) has not shown that
MLC601 could improve the primary outcome but revealed
eﬃciency of the drug on the early recurrent vascular
events in post-stroke patients (Chen et al., 2013b). In addi-
tion a further analysis within the CHIMES trial on morethan 500 patients with more prognostic factors for poorer
outcome indicates a beneﬁcial eﬀect of MLC601
(Navarro et al., 2014). Recent preclinical studies on
MLC601/901 provide a solid scientiﬁc support to the pro-
posed use of this therapeutic compound against stroke
(Heurteaux et al., 2013).
The present study indicates that MLC901 induces a
brain protection against the deleterious eﬀects induced
by TBI and enhances neurological recovery. The LFP
brain injury model used in that work is highly
reproducible and a well-characterized model of
experimental traumatic brain injury (Dixon et al., 1987).
MLC901 strongly ameliorated the histopathological
results, highlighted by a decrease of the brain lesion vol-
ume. In this model of moderate TBI, the lesions were
maximal in the cortical area surrounding the impact site
and in the hippocampus, ipsilateral to the impact site. This
ﬁnding is in accordance with previous observations
(McIntosh et al., 1989).
S100B and NSE have been proposed as potential
predictive biomarkers of recovery in traumatic brain
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protein found in astroglia and Schwann cells, is a marker
of brain damage and glial activation. Clinically, several
reports have found a correlation between serum S100B
level and the outcome of patients (Raabe et al., 1998;
Woertgen et al., 1999; Rothermundt et al., 2003). NSE
is a cytoplasmic glycolytic enzyme of neurons, which is
passively released into the extracellular space, only under
pathological conditions. Increased levels of NSE have
been found in blood of patients after TBI correlating with
clinical outcome (Herrmann et al., 2001; Vos et al.,
2004; Berger et al., 2006). However, conﬂicting results
have also been reported showing no diﬀerence between
control and patients (Ross et al., 1996; Raabe et al.,
1998). In the present study, TBI in rats induced increases
of both S100B and NSE proteins and MLC901 treatment
largely eliminated these TBI-induced variations. This
result suggests a positive eﬀect of MLC901 on the out-
come in rats after TBI by decreasing the deleterious con-
sequences induced by TBI from severe to moderate or
mild.
Another consequence of TBI is the appearance of
cerebral edema, which is one of the most critical factors
in patient’s morbidity and mortality. The degree and
extent of edema correlates with a negative clinical
outcome (Marmarou et al., 2007). Occurring within the
closed conﬁnes of the skull and meninges, overall brain
swelling leads to life-threatening cessation of the brain
blood supply due to raised intracranial pressure and dam-
age to cerebral tissue. In rodents and humans, the devel-
opment of a massive brain edema after TBI is associated
with a biphasic pathophysiological response. First, there
is a brief period of increased water diﬀusion distance
caused by the transient opening of the blood–brain bar-
rier, which produces predominantly vasogenic edema for-
mation, immediately after injury. Second, at
approximatively 45 min post-injury, a more widespread
and slower cellular edema formation, caused by neuro-
toxic edema and astrocytic swelling is initiated and is sus-
tained one or two weeks after TBI (Barzo et al., 1997;
Marmarou et al., 2006). This work shows that edema
was signiﬁcantly reduced after a MLC901 treatment,
decreasing the risk of uncontrolled high intracranial pres-
sure. One critical mediator of post-traumatic edema is
AQPs, and particularly AQP4 (Fukuda and Badaut,
2012). AQPs are water channels that are involved in the
prevention and the resolution of edema (Badaut et al.,
2011). Twenty four hours after traumatic brain injury a
decrease of AQP4 immunostaining is observed, speciﬁ-
cally in regions aﬀected by the BBB break-down, whereas
an increase appears on the border of the insult 3 days
after injury (Ke et al., 2001). Interestingly, as compared
to vehicle, MLC901 induced a signiﬁcant decrease of
AQP4 expression in the ﬁrst hours after TBI followed by
an increase one week later. As already observed after a
post-TBI treatment with anti-AQP4 antibodies (Shenaq
et al., 2012) the early decrease of AQP4 after brain
trauma may be an indication of a protective eﬀect against
vasogenic edema formation, whereas the late increase
could be essential for long-term cytotoxic edema resolu-
tion (Taniguchi et al., 2000; Ke et al., 2001). These datasuggest a potential role of MLC901 during edema resolu-
tion by acting on AQP4 expression which would be
expected to facilitate water extravasations from the brain
parenchyma to liquid compartments including blood ves-
sels and CSF.
It is now well accepted that the functional recovery
that occurs spontaneously after brain injury (stroke or
TBI) is due to the plasticity of surviving neurons, lesion-
induced plasticity, and/or plasticity of neural connections
(Murphy and Corbett, 2009; Schoch et al., 2012). The pro-
liferation of newly generated cells contributes to the over-
all cellular remodeling that occurs after TBI (Richardson
et al., 2010). We observed that the proximal injury zone
is marked largely by newly generated cells. In addition,
more distal to the injury area we observed a neurogenesis
which occurs within the subgranular zone of the dentate
gyrus. The newly generated cells diﬀerentiate into mature
DG granule cells which form synapses and send axons to
their target region CA3, indicating their successful integra-
tion into the existing neuronal circuitry. These results sug-
gest that MLC901 treatment stimulates both gliogenesis
and neurogenesis, which probably help in inducing a
dynamic brain remodeling and lead to a better neurologic
recovery in the ﬁrst weeks after TBI. The positive eﬀects
of MLC901 on neuronal plasticity (as characterized by
increased neurogenesis, neurite outgrowth, axonal
sprouting, dendritic arborization and/or synaptogenesis)
has already been observed following focal and global
ischemia and correlated to functional recovery
(Heurteaux et al., 2010; Quintard et al., 2011). The growth
promoting factors such as BDNF and VEGF are key medi-
ators to support adaptive remodeling of surviving neurons
and neural networks, which beneﬁts the recovery pro-
gress (Conte et al., 2003; Chopp et al., 2009). VEGF is
a key mediator of tissue repair after brain injury and is
known to play a critical role in angiogenesis (Greenberg
and Jin, 2005). An upregulation of BDNF induced by a
MLC901 treatment has been previously reported in the
context of brain injury caused by stroke and cardiac arrest
(Heurteaux et al., 2010; Quintard et al., 2011). In the pres-
ent work we show that MLC901 increases the expression
of VEGF, suggesting that MLC901’s eﬀects on this neuro-
trophic factor could be, at least partially, responsible for
beneﬁts observed after this treatment.
It is known that neuronal damage induced by TBI
associated to post-traumatic cellular dysfunctions leads
to behavioral impairments in rodents, which reﬂect
motor and cognitive deﬁcits observed in humans.
Impairments in learning and memory (including
impairments in short-term memory, speed of information
processing, attention and executive functions) occur in
as many as 50% of patients following TBI (McAllister
et al., 2006). Similar impairments occur in rodent models
(Morales et al., 2005). MLC901 has been previously
reported to decrease neurologic deﬁcits and improve
recovery after stroke and cardiac arrest in rodents
(Heurteaux et al., 2010; Quintard et al., 2011). In the pres-
ent work we determined the potential eﬀects of MLC901
on TBI-induced episodic memory impairments. Episodic
memory is a complex cognitive skill integrating the spatial
(‘‘where’’) and temporal (‘‘when’’) aspects as well as the
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ruption commonly observed in traumatic brain-injured
patients (Arenth et al., 2012) can be particularly handicap-
ping. In the current study we used a new approach of
behavior with a modiﬁed version of the novel object recog-
nition task (NORT) which allows to investigate the ‘‘what-
where-when’’ dimensions of episodic memory in rodents
(Dere et al., 2005; Kart-Teke et al., 2006). Consistent with
previous data obtained in the classical version of the
object recognition task (Davis et al., 2010), this work
clearly indicates that TBI rats showed a decrease in
object exploration during the sample trials. They also dis-
played a total suppression of temporal order memory,
which had already been observed in cranially injured rats
submitted to an olfactory preference task (Gurkoﬀ et al.,
2012) and in TBI patients (Schmitter-Edgecombe and
Seelye, 2012). While MLC901 failed to reverse the TBI-
induced exploratory impairment, it completely restored
the temporal order memory demonstrating that its physio-
logical curative/protective eﬀects were translated in
behavioral improvement.
The lack of discrimination between both ‘‘displaced’’
and ‘‘stationary’’ old objects in vehicle-treated sham rats
suggests that the spatial characteristics of our task were
probably too challenging (visual cues not clear enough,
displacement of the displaced object too short. . .) and
exceeded their cognitive capacities. It might be
surprising at ﬁrst sight to observe that the cognitive
capabilities of sham rats were diﬀerent for temporal
order memory and object location (spatial) memory. A
probable explanation is that the ﬁne neurobiological
circuitries underlying the two types of memory are not
totally identical. They seem to be processed by diﬀerent
subregions of the hippocampus (Howland et al., 2008).
While the ventral hippocampus is crucial for temporal
order memory, it is not for the object location (spatial)
memory. In the same way, the medial prefrontal cortex is
more crucially involved in the temporal order memory than
in the object location (spatial) memory (Barker and
Warburton, 2011). The segregation of neurobiological
substrates for the diﬀerent types of memory could
account, at least in part, for the diﬀerence of behavior
observed in the present work. In contrast, the capacity of
MLC901-treated sham rats, conserved in MLC901-treated
TBI rats, to eﬃciently acquire object location (spatial)
memory suggests a pro-cognitive eﬀect of MLC901. This
would be consistent with the fact that hippocampal neuro-
genesis and elevated BDNF secretion are both stimulated
by MLC901 (Heurteaux et al., 2010; Quintard et al., 2011)
and are known to improve spatial discrimination and con-
solidation of spatial memory by hippocampus (Garthe
et al., 2009; Sahay et al., 2011; Ozawa et al., 2014).CONCLUSION
This work provides evidence that MLC901 has
neuroprotective and neurorestorative actions which lead
to an improvement in the recovery of cognitive functions
in a rat model of traumatic brain injury and a rationale
for exploring MLC901 therapy to improve recovery of
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